The human intestine hosts a diverse microbial community that supports metabolism and digestion. Disruption of this microbiome can lead to liver diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic liver disease, and cirrhosis. Factors like the Western diet and alcohol contribute to microbiome dysbiosis, which causes intestinal inflammation, barrier dysfunction, and microbial translocation. The microbiome's role in liver disease extends beyond bacterial translocation, involving microbial metabolites and host factors. The microbiome's composition is altered in liver diseases, with specific changes observed in NAFLD and NASH patients. These changes include reduced Ruminococcaceae bacteria and increased Escherichia in obese children with NASH. In contrast, adult NASH patients show higher Clostridium coccoides levels. Intestinal bacterial overgrowth is more prevalent in NAFLD and NASH patients, correlating with disease severity. In alcoholic liver disease, microbiome changes include reduced Bacteroidaceae in alcoholic patients. Animal studies show that ethanol intake alters the microbiome, reducing probiotic bacteria and increasing bacterial overgrowth. Probiotics may reduce liver injury in animal models. In cirrhosis, bacterial overgrowth is common, contributing to endotoxemia and complications. The microbiome's role in liver disease is complex, involving interactions with bile acids, immune responses, and metabolic pathways. Modulating the microbiome could offer therapeutic strategies for liver diseases. Future research should focus on understanding the microbiome's role in liver disease and developing targeted interventions.The human intestine hosts a diverse microbial community that supports metabolism and digestion. Disruption of this microbiome can lead to liver diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic liver disease, and cirrhosis. Factors like the Western diet and alcohol contribute to microbiome dysbiosis, which causes intestinal inflammation, barrier dysfunction, and microbial translocation. The microbiome's role in liver disease extends beyond bacterial translocation, involving microbial metabolites and host factors. The microbiome's composition is altered in liver diseases, with specific changes observed in NAFLD and NASH patients. These changes include reduced Ruminococcaceae bacteria and increased Escherichia in obese children with NASH. In contrast, adult NASH patients show higher Clostridium coccoides levels. Intestinal bacterial overgrowth is more prevalent in NAFLD and NASH patients, correlating with disease severity. In alcoholic liver disease, microbiome changes include reduced Bacteroidaceae in alcoholic patients. Animal studies show that ethanol intake alters the microbiome, reducing probiotic bacteria and increasing bacterial overgrowth. Probiotics may reduce liver injury in animal models. In cirrhosis, bacterial overgrowth is common, contributing to endotoxemia and complications. The microbiome's role in liver disease is complex, involving interactions with bile acids, immune responses, and metabolic pathways. Modulating the microbiome could offer therapeutic strategies for liver diseases. Future research should focus on understanding the microbiome's role in liver disease and developing targeted interventions.